Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

NCT03117361 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT03117361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03117361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Lead sponsor
PharmaMar
Phase
Phase 2
Overall status
Terminated
Start date
May 8, 2017
Completion date
July 30, 2018
Enrollment
10 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma